Lymphoproliferative Disorders × Lymphoid × Clear all
NCT04904588 2026-03-18

ACCESS

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
300 enrolled
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Pfizer

Phase 2 Completed
39 enrolled 15 charts
NCT01137643 2025-10-27

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

UNC Lineberger Comprehensive Cancer Center

Recruiting
15,000 enrolled
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT00935090 2025-07-08

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Barbara Ann Karmanos Cancer Institute

Recruiting
NCT01137825 2025-06-25

Registry of Older Patients With Cancer

UNC Lineberger Comprehensive Cancer Center

Recruiting
3,000 enrolled
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
NCT03744676 2025-02-27

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Juno Therapeutics, a Subsidiary of Celgene

Phase 2 Completed
104 enrolled 29 charts